The Life Sciences and M&A teams advised Alkermes plc (Nasdaq: ALKS) in its completed separation of its oncology business into Mural Oncology plc, a new, independent, publicly traded company. Alkermes is now a pure-play, profitable, neuroscience company that will continue its work to develop innovative medicines for people living with difficult-to-treat psychiatric and neurological disorders. Mural Oncology will begin “regular way” trading on the Nasdaq Global Market under the stock ticker symbol “MURA” on Nov. 16, 2023. Alkermes will continue to trade under the Nasdaq ticker symbol “ALKS.”
Upon completion of the separation, each of Alkermes’ shareholders received a distribution of one ordinary share of Mural Oncology for every 10 ordinary shares of Alkermes held as of the close of business on Nov. 6, 2023, the record date for the distribution.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders.
The Goodwin team was led by Robert Puopolo, Blake Liggio, Caitlin Tompkins and Stephanie Richards and included Katherine Hand, Sam Beavers, Ana Caroline Gentil Zattar, Daniela Sanchez, Monika Chawla, Frank Qin, Marishka DeToy, Kathryn Clerici, Zachary Ota, Daniel Karelitz, Gregg Coughlin, Nicole Brock, Alicia Wi, Alexandra Denniston, Morgan Frisoli, Chris Jones, Timothy Holahan, Susan Lee, Julie Tibbets, Timothy Worden, Lucy Sharples, Roger Cohen, Heath Ingram, Simone Otenaike, Chris Denn, Adam Bellack, Alison Liou, Gretchen Scott, Jacqueline Klosek, Joseph Ndep, Caroline Bullerjahn, Joe Rockers, Brendan Lally-McGurl, Justin Ward, and Ettore Santucci and James Matarese with invaluable assistance from Nathan Needle, Madison Clausius, and Matt Salit.
For additional details on the transaction, please read the press release.